<DOC>
	<DOCNO>NCT01853228</DOCNO>
	<brief_summary>The purpose study examine safety efficacy decitabine sequential administration cytarabine child relapse refractory acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>A Study Decitabine ( DACOGEN ) Sequential Administration With Cytarabine Children With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) study evaluate safety , efficacy , pharmacokinetics ( study body drug ) decitabine sequential administration cytarabine child relapse refractory AML . The study determine maximum tolerate dose cytarabine give follow decitabine ( Phase 1 ) response rate combination ( Phase 2 ) . Participants may enter continuation phase single agent-decitabine infusion long treatment would consider beneficial . Serial pharmacokinetic sample collect safety efficacy monitor throughout study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histological diagnosis acute myeloid leukemia ( AML ) accord World Health Organization ( WHO ) classification Diagnosis AML relapse refractory standard care curative therapy exist Karnofsky Lansky score least 50 Must recover acute toxicity prior treatment Must adequate organ function accord protocoldefined criterion Agrees protocoldefined use effective contraception Female participant childbearing potential must negative serum urine pregnancy test Day 1 Cycle 1 Prior treatment decitabine azacitidine Acute promyelocytic leukemia ( M3 subtype FrenchAmericanBritish [ FAB ] classification system ) CNS3 disease acute myeloid leukemia ( AML ) associate congenital syndrome Down syndrome , Fanconi anemia , Bloom syndrome , Kostmann syndrome DiamondBlackfan anemia , bone marrow failure associate inherited syndrome White blood cell count great 40x10^9 cells/liter ( L ) Known allergy , hypersensitivity , intolerance decitabine cytarabine excipients Contraindications use cytarabine per local prescribing information prior adverse reaction cytarabine would prevent use Currently enrol treatment phase interventional investigational study Female pregnant , breastfeeding , plan become pregnant enrolled study within 3 month last dose study drug ( however , period become safe become pregnant last dose treatment know ) Male plan father child enrol study within 3 month last dose study drug Any condition , opinion investigator , participation would best interest patient could prevent , limit , confound protocolspecified assessment Any social medical condition investigator 's opinion render participant unfit study participation History hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) positive , clinically active liver disease History human immunodeficiency virus ( HIV ) antibody positive</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Relapsed refractory acute myeloid leukemia</keyword>
	<keyword>Children</keyword>
	<keyword>Decitabine</keyword>
	<keyword>DACOGEN</keyword>
	<keyword>Cytarabine</keyword>
</DOC>